NFL Biosciences, a biopharmaceutical company developing botanical drugs for addiction treatment, has secured €0.5 million in debt financing from Bpifrance. This non-dilutive funding will support the preparation for a Phase 2 clinical trial submission for their drug candidate, NFL-102, anticipated in mid-2026.
Amount: $500.0K
